Find Vibegron manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1190389-15-1, Krp-114v, Gemtesa, Mk-4618, (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide, M5tse03w5u
Molecular Formula
C26H28N4O3
Molecular Weight
444.5  g/mol
InChI Key
DJXRIQMCROIRCZ-XOEOCAAJSA-N
FDA UNII
M5TSE03W5U

Vibegron
Vibegron is a potent, selective beta-3 adrenergic receptor (3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary frequency, and reduced quality of life of patients. On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012. Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.
1 2D Structure

Vibegron

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
2.1.2 InChI
InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
2.1.3 InChI Key
DJXRIQMCROIRCZ-XOEOCAAJSA-N
2.1.4 Canonical SMILES
C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
2.1.5 Isomeric SMILES
C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O
2.2 Other Identifiers
2.2.1 UNII
M5TSE03W5U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Mk-4618

2. N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide

2.3.2 Depositor-Supplied Synonyms

1. 1190389-15-1

2. Krp-114v

3. Gemtesa

4. Mk-4618

5. (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide

6. M5tse03w5u

7. C26h28n4o3

8. Mk4618

9. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide

10. Pyrrolo(1,2-a)pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)-2-pyrrolidinyl)methyl)phenyl)-4-oxo-, (6s)-

11. Beova

12. Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6s)-

13. Vibegron [usan]

14. Vibegron [usan:inn]

15. Unii-m5tse03w5u

16. Vibegronum

17. Beova (tn)

18. Mk 4618

19. Vibegron (jan/usan)

20. Vibegron [inn]

21. Vibegron [jan]

22. Vibegron [who-dd]

23. Vibegron [orange Book]

24. Chembl2107826

25. Schembl11985457

26. Gtpl10100

27. Dtxsid40152299

28. Chebi:142418

29. Ex-a3390

30. Bdbm50146154

31. Mfcd28502057

32. At23148

33. Compound 7 [pmid: 26709102]

34. Db14895

35. Hy-19933

36. Cs-0016926

37. D10433

38. A903957

39. Q27283524

40. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-pyrrolo[1,2-a]pyrimidine-6-carboxamide

41. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide

42. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl(methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-

43. (6s)-n-[4-({(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide

44. (6s)-n-[4-[[(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6h-pyrrolo[1,2-a]pyrimidine-6-carboxamide

2.4 Create Date
2009-11-30
3 Chemical and Physical Properties
Molecular Weight 444.5 g/mol
Molecular Formula C26H28N4O3
XLogP31.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass444.21614077 g/mol
Monoisotopic Mass444.21614077 g/mol
Topological Polar Surface Area94 Ų
Heavy Atom Count33
Formal Charge0
Complexity782
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Vibegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Vibegron selectivity for beta-3 adrenergic receptors is >9000 times higher than for 1AR or 2AR. Vibegron improves clinical symptoms of overactive bladder by increasing bladder capacity without affecting bladder contraction. It significantly increases the functional bladder volume in a dose-dependent manner, which results in prolongation of the interval between voids. In clinical studies, vibegron inhibited detrusor bladder contractions in a concentration-dependent manner, reduced voiding pressure, and increased bladder compliance. In Japanese clinical studies comprising patients with overactive bladder, vibegron significantly improved the frequency of micturition, urgency, and urgency incontinence episodes.


5.2 Absorption, Distribution and Excretion

Absorption

The mean Tmax is 1-3 hours. Steady-state concentrations are achieved within 7 days of once-daily dosing.


Route of Elimination

In a radiolabeled drug study, approximately 59% of the radiolabeled dose was recovered in feces, in which 54% of that amount was in the unchanged parent drug form. About 20% of the radioactivity was recovered in urine, in which 19% of the amount was in the unchanged form.


Volume of Distribution

The mean apparent volume of distribution is 6304 L. The average blood-to-plasma concentration ratio is 0.9. According to tissue distribution studies in animals, vibegron does not penetrate the blood-brain barrier, suggesting limited potential for CNS toxicity in humans.


Clearance

There is limited information on the clearance rate of vibegron.


5.3 Metabolism/Metabolites

In vitro, CYP3A4 is the main enzyme responsible for the metabolism of vibegron, which plays a minor role in the elimination of vibegron. Two predominant metabolic pathways are oxidation and glucuronidation to form two oxidative metabolites and three glucuronide metabolites. Metabolites have not been fully characterized.


5.4 Biological Half-Life

The terminal plasma half-life ranges from 60 to 70 hours. The effective half-life is 30.8 hours.


5.5 Mechanism of Action

Overactive bladder is characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency. Bladder filling and emptying are regulated by the coordinated communication between sympathetic and parasympathetic systems. Bladder filling occurs via parasympathetic inhibition and the sympathetic hypogastric nerve releasing norepinephrine, which acts on beta-adrenergic receptors responsible for mediating detrusor muscle relaxation. Symptoms of overactive bladder are thought to be caused by the deterioration of the sensory connections between the bladder, spinal cord and brain, leading to changes in the lower urinary tract and abnormal bladder sensations of the urge to void at small bladder volumes. Beta-3 adrenergic receptors (3ARs) are expressed in the kidneys and lower urinary tract, including ureters, urethra, prostate, and bladder. Vibegron is a selective agonist at 3AR. One vibegron binds to the receptor, 3AR is stimulated and undergoes a conformation change and activates adenylyl cyclases (AC), which promotes the formation of cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP concentration leads to the activation of cAMP-dependent protein kinase A (PKA), which subsequently phosphorylates myosin light chains that are responsible for inhibiting the interaction of actin with myosin dependent on calcium calmodulin complex. In clinical trials, vibegron increased cAMP levels in a dose-proportional manner. There is evidence that 3AR agonists may also work via sensory mechanisms without directly affecting detrusor muscle motor function.


KDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content

Vivegron

Registrant Name : Aging Life Science Co., Ltd.

Registration Date : 2024-11-07

Registration Number : Su434-69-ND

Manufacturer Name : Ami Lifesciences Private Lim...

Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi – 391 45...

AMI Lifesciences

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

non-differentiated

Registrant Name : Lee Sung International Co., Ltd.

Registration Date : 2025-10-10

Registration Number : Su21-34-ND

Manufacturer Name : Honour Lab Limited Unit-III

Manufacturer Address : Plot No.4, Hetero Infrastructure SEZ Ltd, N.Narasapuram Village, Nakkapalli Mandal, A...

Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

non-differentiated

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2025-11-28

Registration Number : Su21-34-ND(1)

Manufacturer Name : Honour Lab Limited Unit-III

Manufacturer Address : Plot No.4, Hetero Infrastructure SEZ Ltd, N.Narasapuram Village, Nakkapalli Mandal, A...

Company Banner

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Vivegron

Registrant Name : Masung LS Co., Ltd.

Registration Date : 2025-02-13

Registration Number : Su163-40-ND

Manufacturer Name : Yangzhou Aurisco Pharmaceuti...

Manufacturer Address : No.28, Jian'an Road, High-Tech Industrial Development Zone, Yangzhou city, Jiangsu Pr...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Vivegron

Registrant Name : Iksoo Pharmaceutical Co., Ltd.

Registration Date : 2026-01-22

Registration Number : Su69-29-ND

Manufacturer Name : Nantong Chanyoo Pharmatech C...

Manufacturer Address : No.2 Tonghai Si Road, Rudong Coastal Economic Development Zone, Nantong, China

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Vivegron

Registrant Name : Ikemi Korea Co., Ltd.

Registration Date : 2025-01-23

Registration Number : Su6191-1-ND

Manufacturer Name : Porton Pharma Solutions Ltd.

Manufacturer Address : 1 Fine Chemical Zone, Chongqing Chemical Industry Park, Changshou, Chongqing 401221, ...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Vivegron

Registrant Name : Jeil Pharmaceutical Co., Ltd.

Registration Date : 2022-10-31

Registration Number : Su216-24-ND

Manufacturer Name : Sumitomo Chemicals Co., Ltd....

Manufacturer Address : 3750, Azajuhachicho, Maki, Ampachicho, Ampachi-Gun, Gifu 503-0125, Japan

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Gemtesa(vibegron) is a beta-3 adrenergic receptor agonist, which is indicated for the treatment of male overactive bladder who are receiving pharmacological therapy for benign prostatic hyperplasia.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 23, 2024

blank

01

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Gemtesa(vibegron) is a beta-3 adrenergic receptor agonist, which is indicated for the treatment of male overactive bladder who are receiving pharmacological therapy for benign prostatic hyperplasia.

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 23, 2024

blank

Details:

Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Obgemsa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 28, 2024

blank

02

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.

Product Name : Obgemsa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 28, 2024

blank

Details:

Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 13, 2024

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Vibegron,Inapplicable

Therapeutic Area : Urology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 13, 2024

blank

Details:

Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Obgemsa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 26, 2024

blank

04

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.

Product Name : Obgemsa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 26, 2024

blank

Details:

Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 11, 2023

blank

05

Sumitomo

Japan
arrow
PEGS Boston Summit
Not Confirmed

Sumitomo

Japan
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Vibegron,Inapplicable

Therapeutic Area : Urology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 11, 2023

blank

Details:

KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the Compound.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Sumitomo

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 06, 2023

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

March 06, 2023

blank

Details:

GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 27, 2022

blank

07

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Details : GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 27, 2022

blank

Details:

Vibegron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neurogenic Detrusor Overactivity.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 08, 2022

blank

08

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Details : Vibegron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neurogenic Detrusor Overactivity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 08, 2022

blank

Details:

Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Obgemsa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Pierre Fabre

Deal Size: $75.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 05, 2022

blank

09

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Details : Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.

Product Name : Obgemsa

Product Type : Miscellaneous

Upfront Cash : Undisclosed

July 05, 2022

blank

Details:

In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.


Lead Product(s): Vibegron,Inapplicable

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 15, 2022

blank

10

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Urovant Sciences

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Details : In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.

Product Name : Gemtesa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 15, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSaiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical int...

CB

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSaiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical int...

CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSaiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.

CAS Number : 1295539-30-8

End Use API : Vibegron

About The Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical int...

CB

04

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Accel Pharmtech, LLC is one of the world’s leading pharmaceutical companies that manufactures and provides their clients and partners with cataloged chemicals...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Hangzhou Hairui Chemical Co., Ltd. is located in the Zhongheng Century Science and Technology Park in Hangzhou, Zhejiang. It is an excellent manufacturer of org...

blank

07

JieJie Group

China
PEGS Boston Summit
Not Confirmed
arrow

JieJie Group

China
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : JieJie Group Co., Ltd. is a pharmaceutical and chemical enterprise for research and production, it was built in 2009. Our core business is custom synthesis and ...

blank

08

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...

blank

09

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...

blank

10

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Pierre Fabre

France
PEGS Boston Summit
Not Confirmed
arrow

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Brand Name : Obgemsa

Dosage Form : Film-Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

02

Pierre Fabre

France
PEGS Boston Summit
Not Confirmed
arrow

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Brand Name : Obgemsa

Dosage Form : Film Coated Tablet

Dosage Strength : 75MG

Packaging :

Approval Date : 30-07-2024

Application Number : 1241822001

Regulatory Info : Authorized

Registration Country : Spain

blank

03

Pierre Fabre

France
PEGS Boston Summit
Not Confirmed
arrow

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Brand Name : Obgemsa

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 27-06-2024

Application Number : 28106959823

Regulatory Info : Prescription

Registration Country : Denmark

blank

04

Pierre Fabre

France
PEGS Boston Summit
Not Confirmed
arrow

Pierre Fabre

France
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Brand Name : Obgemsa

Dosage Form : Film Coated Tablet

Dosage Strength : 75mg

Packaging :

Approval Date : 27-06-2024

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

VIBEGRON

Brand Name : GEMTESA

Dosage Form : TABLET;ORAL

Dosage Strength : 75MG

Packaging :

Approval Date : 2020-12-23

Application Number : 213006

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

VIBEGRON

Brand Name : GEMTESA

Dosage Form : TABLET;ORAL

Dosage Strength : 75MG

Approval Date : 2020-12-23

Application Number : 213006

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
FDA okays 50 new drugs in 2024; BMS’ Cobenfy, Lilly’s Kisunla lead pack of breakthrough therapies
In 2024, the biopharma industry continued to advance on its robust trajectory of innovation. Though the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) approved fewer drugs, there was a significant increase in medical breakthroughs.While the CDER approved 50 new drugs in 2024, as compared to 55 in 2023, the CBER granted 14 biologics approvals in 2024, down from 20 in 2023.The European Medicines Agency (EMA) approved 34 new therapies, up from 32 in 2023, while Health Canada granted 28 approvals, down from 38 in 2023.The year saw long-awaited treatments being approved in areas such as schizophrenia and Alzheimer’s disease in the second half (H2) of 2024. In H1 2024, drugs to treat metabolic dysfunction-associated steatohepatitis (MASH) and chronic obstructive pulmonary disease (COPD) had been granted FDA approvals.As the year drew to a close, FDA began approving drugs at a feverish pace, with 29 of the CDER’s 50 approvals coming in H2.Like most years, the landscape of drug approvals was dominated by oncology, with 15 of the 50 drugs (30 percent) approved targeting various forms of cancer. This was followed by dermatology and non-malignant hematology, each accounting for 12 percent of approvals. Notably, small molecules continued to dominate the market, making up for 64 percent of the new drug approvals, while 32 percent were proteins, including monoclonal and bi-specific antibodies. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available)Karuna-BMS’ schizophrenia drug, Lilly’s Alzheimer’s med, Neurocrine’s Crenessity dominate list of pathbreaking approvals in H2Out of the 50 new drugs approved in 2024, CDER identified 24 (48 percent) as first-in-class, showcasing novel mechanisms of action. The most anticipated approval of 2024 was Karuna and Bristol Myers Squibb’s Cobenfy, a groundbreaking treatment for schizophrenia. This fixed-dose combination of xanomeline and trospium chloride represents the first novel mechanism of action in decades for this debilitating psychiatric condition. Analysts forecast peak annual sales of over US$ 3.3 billion for Cobenfy. Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) became the third amyloid-targeting antibody to gain FDA approval. Unlike its predecessors, Kisunla offers a unique limited-duration treatment regimen, allowing patients to discontinue therapy once amyloid levels in the brain drop below a certain threshold. Priced at approximately US$ 32,000 per year, it is positioned as a cost-effective alternative to existing treatments. Analysts estimate peak sales of US$ 2.4 billion for Kisunla.Crenessity (crinecerfont), developed by Neurocrine Biosciences, became the first FDA-approved treatment in decades for classic congenital adrenal hyperplasia (genetic conditions that affect the adrenal glands). Similarly, Vertex’s triple combination therapy of deutivacaftor, tezacaftor & vanzacaftor (Alyftrek) for cystic fibrosis represents a significant advancement in genetic disease treatment. Analysts forecast peak sales exceeding US$ 8.3 billion, underscoring the therapy’s potential to transform patient care.Meanwhile, Bridgebio’s Attruby (acoramidis hydrochloride) emerged as a promising treatment for cardiac amyloidosis, a life-threatening condition. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Roche’s Itovebi, Checkpoint’s Unloxcyt clinch FDA approvals in H2 2024; forecast to achieve blockbuster statusThe dominance of cancer drug approvals reflects the ongoing focus on targeted therapies, immuno-oncology, and precision medicine to improve outcomes for patients with hard-to-treat cancers.Among the year’s notable FDA approvals was Genentech’s Itovebi (inavolisib), another targeted therapy that treats hormone receptor-positive (HR+), HER2-negative breast cancer. Itovebi is a PI3Kα inhibitor designed specifically for patients with PIK3CA mutations, a common driver of resistance to endocrine therapy in breast cancer. It demonstrated a more tolerable safety profile. Roche projects Itovebi’s peak (annual) sales to reach CHF 2 billion (US$ 2.3 billion).Checkpoint Therapeutics’ Unloxcyt (cosibelimab) joined the crowded checkpoint inhibitor market as the eleventh PD-1/PD-L1-targeting monoclonal antibody approved by the FDA. It was granted approval for cutaneous squamous cell carcinoma (cSCC), an aggressive form of skin cancer with high recurrence rates. As compared to other checkpoint inhibitors, like Keytruda (pembrolizumab) and Opdivo (nivolumab), Unloxcyt is likely to offer an advantage in immune activation.FDA also approved Astellas’ Vyloy (zolbetuximab), a first-in-class monoclonal antibody for metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Analysts forecast peak sales of approximately US$ 850 million for Vyloy.Syndax Pharmaceuticals’ Revuforj (revumenib) was approved by FDA to treat a type of acute leukemia in both adults and children. This approval introduces a novel class of medications known as menin inhibitors. These agents are currently in clinical development for the treatment of genetically defined subsets of acute leukemia. These inhibitors function by preventing the activation of cancer growth-related proteins. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Potential blockbusters Lilly’s Ebglyss, Galderma’s Nemluvio lead advances in dermatologyEli Lilly’s Ebglyss (lebrikizumab) garnered significant attention. Approved by FDA for moderate-to-severe atopic dermatitis, this monoclonal antibody introduces a less burdensome dosing regimen compared to its competitors, with maintenance therapy required only once a month. This feature positions it as a potential contender to Dupixent (dupilumab), a market leader in atopic dermatitis. Ebglyss sales are forecast to reach US$ 1.9 billion by 2030.Galderma’s Nemluvio (nemolizumab) secured FDA approval for two indications in 2024 — prurigo nodularis (a chronic disorder of the skin) and moderate-to-severe atopic dermatitis in patients aged 12 years and older. As the first humanized IgG2 monoclonal antibody targeting the IL-31 receptor, Nemluvio directly inhibits the key driver of itch and inflammation in both these conditions. With its unique mechanism and broad dermatology potential, analysts forecast peak sales of approximately US$ 1.66 billion. Ebglyss and Nemluvio underscore the growing importance of biologics in dermatological care.Botanix Pharmaceuticals also made strides in dermatology by clinching an FDA approval for Sofdra (sofpironium) in June. The drug has been okayed for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive sweating.Ascendis Pharma’s Yorvipath (palopegteriparatide), a therapy approved by FDA to treat hypoparathyroidism, is forecast to achieve blockbuster sales of US$ 1.8 billion by 2030, highlighting its potential to transform endocrine care. View New Drug Approvals in 2024 with Estimated Sales (Free Excel Available) Our viewOverall, 2024 was defined by its breakthrough drug approvals. The year also saw significant reduction in complete response letters (CRLs) — they dropped from 43 in 2023 to just 29 in 2024. This suggests improved industry preparedness and alignment with regulatory expectations.The new year began with the approval of Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo, marking a significant advancement in oncology. Several other promising new drugs are coming up for FDA approval this year, such as J&J’s nipocalimab, Vertex Pharmaceuticals’ suzetrigine, Elevar Therapeutics’ rivoceranib/camrelizumab, Sanofi’s fitusiran and GSK’s gepotidacin. Hopefully, the momentum of breakthrough approvals will continue through 2025, political headwinds in the US notwithstanding. 

Impressions: 13864

https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies

#PharmaFlow by PHARMACOMPASS
30 Jan 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-05-18/new-data-from-sumitomo-pharma-america-at-aua-2026-highlight-efficacy-of-vibegron-in-men-aged-75-and

PHARMIWEB
18 May 2026

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220285

FDA
04 Nov 2025

https://www.fiercepharma.com/marketing/power-couple-peetes-team-promote-sumitomos-gemtesa

FIERCE PHARMA
01 Jul 2025

https://www.prnewswire.com/news-releases/sumitomo-pharma-america-and-former-professional-quarterback-rodney-peete-say-its-time-to-go-and-put-yourself-first-with-overactive-bladder-treatment-option-gemtesa-302494429.html

PR NEWSWIRE
30 Jun 2025

https://www.prnewswire.com/news-releases/sumitomo-pharma-america-presents-new-data-on-vibegron-at-the-2025-american-urological-association-annual-meeting-302440736.html

PR NEWSWIRE
29 Apr 2025

https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-gemtesa-tablets-82160.pdf

FDA
20 Feb 2025

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed

Company : Urovant-Sumitom

Vibegron

Drug Cost (USD) : 508,474,527

Year : 2023

Prescribers : 187161

Prescriptions : 758224

blank

02

Brand Name : Gemtesa

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Company : Urovant Science

Vibegron

Drug Cost (USD) : 164,478,183

Year : 2022

Prescribers : 70495

Prescriptions : 274340

blank

03

Brand Name : Gemtesa

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Company : Urovant Science

Vibegron

Drug Cost (USD) : 28,352,679

Year : 2021

Prescribers : 19287

Prescriptions : 50721

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Gemtesa

Vibegron

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Main Therapeutic Indication : Urology

Currency : USD

2021 Revenue in Millions : 35

2020 Revenue in Millions : 0

Growth (%) : 100

blank

02

Brand Name : Gemtesa

Vibegron

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Main Therapeutic Indication : Urology

Currency : USD

2022 Revenue in Millions : 153

2021 Revenue in Millions : 35

Growth (%) : 332

blank

03

Brand Name : Gemtesa

Vibegron

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Main Therapeutic Indication : Urology

Currency : USD

2023 Revenue in Millions : 55

2022 Revenue in Millions : 153

Growth (%) : -59

blank

04

Brand Name : Gemtesa

Vibegron

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Gemtesa

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Vibegron

Main Therapeutic Indication : Urology

Currency : USD

2024 Revenue in Millions : 360

2023 Revenue in Millions : 254

Growth (%) : 42

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1190389-15-1 / Vibegron API manufacturers, exporters & distributors?

Vibegron manufacturers, exporters & distributors 1

75

PharmaCompass offers a list of Vibegron API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vibegron manufacturer or Vibegron supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vibegron manufacturer or Vibegron supplier.

API | Excipient name

Vibegron

Synonyms

1190389-15-1, Krp-114v, Gemtesa, Mk-4618, (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide, M5tse03w5u

Cas Number

1190389-15-1

Unique Ingredient Identifier (UNII)

M5TSE03W5U

About Vibegron

Vibegron is a potent, selective beta-3 adrenergic receptor (3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary frequency, and reduced quality of life of patients. On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012. Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.

Vibegron Manufacturers

A Vibegron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vibegron, including repackagers and relabelers. The FDA regulates Vibegron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vibegron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Vibegron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Vibegron Suppliers

A Vibegron supplier is an individual or a company that provides Vibegron active pharmaceutical ingredient (API) or Vibegron finished formulations upon request. The Vibegron suppliers may include Vibegron API manufacturers, exporters, distributors and traders.

click here to find a list of Vibegron suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Vibegron USDMF

A Vibegron DMF (Drug Master File) is a document detailing the whole manufacturing process of Vibegron active pharmaceutical ingredient (API) in detail. Different forms of Vibegron DMFs exist exist since differing nations have different regulations, such as Vibegron USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Vibegron DMF submitted to regulatory agencies in the US is known as a USDMF. Vibegron USDMF includes data on Vibegron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vibegron USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Vibegron suppliers with USDMF on PharmaCompass.

Vibegron KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Vibegron Drug Master File in Korea (Vibegron KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vibegron. The MFDS reviews the Vibegron KDMF as part of the drug registration process and uses the information provided in the Vibegron KDMF to evaluate the safety and efficacy of the drug.

After submitting a Vibegron KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vibegron API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Vibegron suppliers with KDMF on PharmaCompass.

Vibegron WC

A Vibegron written confirmation (Vibegron WC) is an official document issued by a regulatory agency to a Vibegron manufacturer, verifying that the manufacturing facility of a Vibegron active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vibegron APIs or Vibegron finished pharmaceutical products to another nation, regulatory agencies frequently require a Vibegron WC (written confirmation) as part of the regulatory process.

click here to find a list of Vibegron suppliers with Written Confirmation (WC) on PharmaCompass.

Vibegron NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vibegron as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Vibegron API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Vibegron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Vibegron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vibegron NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Vibegron suppliers with NDC on PharmaCompass.

Vibegron GMP

Vibegron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vibegron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vibegron GMP manufacturer or Vibegron GMP API supplier for your needs.

Vibegron CoA

A Vibegron CoA (Certificate of Analysis) is a formal document that attests to Vibegron's compliance with Vibegron specifications and serves as a tool for batch-level quality control.

Vibegron CoA mostly includes findings from lab analyses of a specific batch. For each Vibegron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vibegron may be tested according to a variety of international standards, such as European Pharmacopoeia (Vibegron EP), Vibegron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vibegron USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty